Silva, Francisco <br/><br/>
TNF-α blocker therapy and solid malignancy risk in ANCA-associated vasculitis.  [electronic resource] 

 -  Current rheumatology reports  Dec 2012 
 - 501-8 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1534-6307 
<br/><br/><label>Standard No.: </label>10.1007/s11926-012-0290-2  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adalimumab<br/>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis--drug therapy<br/>Antibodies, Monoclonal--adverse effects<br/>Antibodies, Monoclonal, Humanized--adverse effects<br/>Antirheumatic Agents--adverse effects<br/>Etanercept<br/>Granulomatosis with Polyangiitis--drug therapy<br/>Humans<br/>Immunoglobulin G--adverse effects<br/>Infliximab<br/>Neoplasms--epidemiology<br/>Receptors, Tumor Necrosis Factor<br/>Risk Factors<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors